GILD

How the FDA’s Delay of Baricitinib Impacts Eli Lilly and Incyte

by

Image Source: Paul Sableman The FDA dealt Eli Lilly and Incyte an unforeseen blow recently by rejecting their marketing application for Rheumatoid Arthritis candidate Baricitinib. Where does the duo go from here? By Alexander J. Poulos an Kris Rosemann The drug approval process is chock full of pitfalls, and until regulators give the final okay, anything can happen. The widely held consensus was Eli Lilly’s (LLY) and Incyte’s (INCY) marketing application for Rheumatoid Arthritis candidate Baricitinib would be approved, but the FDA shocked everyone by issuing a complete response letter requesting further data. Where does the duo of Eli Lilly and Incyte proceed from here? Baricitinib We were optimistic the FDA would approve Baricitinib for the indication of Rheumatoid Arthritis … Read more

Dividend Increases/Decreases for the Week of February 3

by

Below we provide a list of firms that raised their dividends during the week ending February 3. The dividend reports of covered firms on this list will be updated shortly with the new information. To access our dividend reports use the ‘Symbol’ search box in our website header. Firms Raising Their Dividends This Week                AFLAC (AFL): now $0.42 per share quarterly dividend, was $0.40. ALLETE (ALE): now $0.6775 per share quarterly dividend, was $0.6500. American Financial (AFG): now $4.00 per share special dividend, was $0.63. Avista (AVA): now $0.46 per share quarterly dividend, was $0.44. Bank of Botetourt (BORT): now $0.1925 per share quarterly dividend, was $0.1850. BCE (BCE): now CAD 0.9675 per share quarterly dividend, was CAD 0.9200. … Read more

Dividend Increases/Decreases for the Week of February 14

by

Below we provide a list of firms that raised their dividends during the week ending February 14. The dividend reports of covered firms on this list will be updated shortly with the new information. To access our dividend reports use the ‘Symbol’ search box in our website header. Firms Raising Their Dividends This Week                          Acadia Realty Trust (AKR): now $0.20 per share quarterly dividend, was $0.19. American Business Bank (AMBZ): now $0.25 per share quarterly dividend. American Homes 4 Rent (AMH): now $0.30 per share quarterly dividend, was $0.26. AstraZeneca (AZN): now $1.03 per share semi-annual dividend, was $0.50. Avista (AVA): now $0.49 per share quarterly dividend, was $0.47. Brookfield (BN): now $0.09 per share quarterly dividend, was … Read more

SEC Approves Financial Weapon of Mass Destruction and More Earnings Reports

by

Let’s talk about quadruple-leveraged ETFs, Apple’s and Altria’s earnings reports, Coach’s fundamental improvement, Gilead’s fall from grace, IBM’s ongoing deterioration and more. By Brian Nelson, CFA Well, it is what it is as they say. In our ETF research and analysis, we consistently warn readers about the long-term price erosion dynamics of ultra-leveraged ETFs (of the double and triple variety), vehicles that we have emphasized are for “day traders,” not long-term investors. Believe it or not, however — we received news May 3 that the SEC approved a request to now list quadruple-leveraged ETFs, what we describe to be “financial weapons of mass destruction.” Yikes. You read that correctly–quadruple-leveraged exchange traded funds, ones that mimic the movement of the index … Read more

There Is Milk At The Store

by

This article first appeared in the September edition of the High Yield Dividend Newsletter. For more information about this publication, please see here. “Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.” — Winston Churchill By Brian Nelson, CFA Very few of us could have imagined that we’d witness the bull market that began on that fateful day in March 2009 that might very well mark a generational low. In 2009, major investment banks around the globe were struggling to survive, and the fallout in the mortgage markets left the banks holding paper that nobody wanted to own, let alone buy. The global financial system … Read more

Valuentum: Now Bearish, We’ve Been Here Every Step of the Way

by

Valuentum Has Been Here Every Step of the Way   From the COVID-19 top in February 2020 to the COVID-19 bottom to the massive bull run through the end of 2021, we’ve been here for you.    2022 started out to be a rough year, catching many by surprise.   But Valuentum stayed positive. When the markets headed south in June, Valuentum stood its ground. On June 14, Valuentum said that “we still believe stocks could make a “huge rebound” in the near term.   We reiterated our views a few days later and on June 19, we said that “investors shouldn’t panic during this bear market” and that “stocks remain an attractive proposition at the moment and a very attractive consideration … Read more

Dividend Increases/Decreases for the Week Ending February 9

by

Below we provide a list of firms that raised their dividends during the week ending February 9. The dividend reports of covered firms on this list will be updated shortly with the new information. To access our dividend reports use the ‘Symbol’ search box in our website header. Firms Raising Their Dividends This Week Allegion (ALLE): now $0.21 per share quarterly dividend, was $0.16. Allergan (AGN): now $0.72 per share quarterly dividend, was $0.70. Allstate (ALL): now $0.46 per share quarterly dividend, was $0.37. ALPS Alerian MLP ETF (AMLP): now $0.2066 per share quarterly dividend, was $0.2052. Anadarko Petroleum (APC): now $0.25 per share quarterly dividend, was $0.05. Archer Daniels Midland (ADM): now $0.335 per share quarterly dividend, was $0.32. … Read more

Best Idea Vertex Pharma Boosts Guidance (Again), Buying Back Stock While Awaiting Key Clinical Trials

by

Image Shown: Vertex Pharmaceuticals Inc is one of our favorite biotech ideas. Image Source: Vertex Pharmaceuticals Inc – Third Quarter of 2021 IR Earnings Presentation By Callum Turcan One of our favorite biotech plays out there is Vertex Pharmaceuticals Inc (VRTX), which is included as an idea in the Best Ideas Newsletter portfolio. The company’s commercial portfolio, meaning therapeutics that have already been approved by key health regulators, is centered on drugs that treat cystic fibrosis (‘CF’), including patients as young as four months old as well as older patients. Its branded commercialized CF treatments include TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO. Vertex Pharma is currently generating substantial revenue and cash flows from these offerings. Guidance Update Sales of its CF … Read more